

FORMULATION OF THYMOQUINONE-LOADED
PLGA NANOPARTICLES AND CYTOTOXICITY IN
MALIGNANT MELANOMA A375 CELL LINE

BY

LUQMAN MUIZZUDDIN BIN MOHD ROSLI

A thesis submitted in fulfillment of the requirement for the
degree of Master in Pharmaceutical Sciences
(Pharmaceutical Technology)

Kulliyyah of Pharmacy
International Islamic University Malaysia

JUNE 2020

ABSTRACT

Background: Thymoquinone (TQ) has been known to have various therapeutic benefits but it is prone to fast degradation. TQ exhibited anticancer effect in several cancer cell lines. Encapsulation of TQ enhances its stability and provides a tool for targeting to the cancer tissues. **Objective:** To prepare and optimize TQ- poly-lactide-co-glycolide (PLGA) nanoparticle (NP) formulation and evaluate it in A375 cells for cell uptake and cytotoxicity. **Methodology:** TQ- PLGA NP formulation was prepared using solvent evaporation method and TQ quantification method was validated using HPLC. The total of 6 factors affecting the formulation (chitosan concentration (A), ratio of co-stabilizer (tween 80: polyvinyl alcohol (B), stabilizer concentration (C), ratio of co-solvents (ethyl acetate: dichloromethane) (D), sonication power (E) and sonication time (F), were screened using fractional factorial design. The screened factors were reduced to 3 most significant (A, C and E) affecting critical output responses of particle size, zeta potential and encapsulation efficiency. An optimized TQ-PLGA NP was prepared by altering these significant factors using full factorial design and targeted responses was acquired and it was proceed for cell uptake studies by flow cytometer and fluorescence microscope; and cell cytotoxicity studies by MTT assay. **Results and discussion:** Optimized TQ-PLGA NP formulation was prepared using 1.02 % w/v chitosan, 1.14% w/v stabilizer and 31% of sonication power. The rest of the parameters were fixed as 1:3 oil to aqueous phase ratio, 1:5 primary emulsion to dispersion medium ratio, 3% w/v PLGA concentration and 75:25 co-solvent ratios of ethyl acetate and dichloromethane. TQ-PLGA NP exhibited particle size of 147.2 ± 0.4 nm; polydispersity index (PDI) of 0.142 ± 0.017 ; zeta potential of 22.1 ± 1.1 ; encapsulation efficiency of 96.81 ± 0.05 %; biphasic release of $56.7 \pm 1.3\%$ (24 h) and $69.7 \pm 1.3\%$ within 1 week. The optimized formulation was aggregated in powdered form but stable in the suspension form up for 10 days. The formulation exhibited lower glass transition of PLGA below 37°C suggesting a plasticizing effect of TQ and other ingredients which contributes to the overall rapid release. TQ in methanol and TQ-PLGA NP in complete growth media were tested for stability. TQ degraded by 18% (24 h) and 77.0% (48 h), particle size remains stable in 24 h, significant changes occurred after 48 h ($p < 0.05$), PDI changes were significant post 24 h and 48 h ($p < 0.05$), significant changes on zeta potential were observed on higher concentration of TQ-PLGA NPs ($p < 0.05$). The highest intracellular uptake was at 1.0 mg/mL NP concentration with time-dependent cell uptake up to 24 h. Post 24 h treatment, the IC₅₀ of TQ-PLGA NP and TQ-solution was calculated to be 4.428 mg/mL and 91.71 $\mu\text{g/mL}$ respectively. At 48 h treatment, IC₅₀s of TQ-PLGA NP was calculated to be 7.981 mg/mL and 58.657 mg/mL respectively. **Conclusion:** Optimized TQ-PLGA NP was formulated and it showed a promising cytotoxic effect in A375 cells. TQ in nanoparticle formulation has a potential use as anticancer and worth a further study in animal models.

خلاصة البحث

الخلفية: من المعروف أن الثيموكينون (TQ) له فوائد علاجية مختلفة ولكنه عرضة للتدهور السريع. أظهر TQ تأثيراً مضاداً للسرطان في العديد من خطوط الخلايا السرطانية. يعزز كبسلة TQ من استقراره ويوفر أداة لاستهداف الأنسجة السرطانية. **الهدف:** إعداد وتحسين تركيبة الجسيمات النانوية (NP) المؤلفة من TQ مع بولي-لاكتايد-كو-جليكولايد (PLGA) وتقييمها في خلايا A375 بناء على الامتصاص الخلوي والسمية الخلوية. **المنهجية:** تم تحضير تركيبة جسيمات PLGA-TQ النانوية باستخدام طريقة تبخير المذيبات وتم التحقق من طريقة قياس TQ الكمية باستخدام HPLC. باستخدام التصميم الجزئي للعوامل تم فحص 6 عوامل مؤثرة على التركيبة: (أ) تركيز الشيتوزان، (ب) نسبة المثبت النانوية (توين 80: كحول البولي فينيل، (ج) تركيز المثبت، (د) نسبة المذيبات النانوية (إيثيل الأسيتات:ثنائي كلورو الميثان)، (هـ) قوة الصوتنة، (و) ومدة الصوتنة. وتم تصفية العوامل التي تم فحصها إلى الثلاثة الأكثر أهمية (أ، ب، ج) والتي تؤثر على استجابات النواتج الحرجة لكل من حجم الجسيمات، وكمون زيتا، وكفاءة الكبسلة. تم تحضير جسيمات TQ-PLGA النانوية عن طريق تغيير هذه العوامل الهامة باستخدام التصميم العامل الجزئي وقد تم الحصول على الاستجابات المستهدفة والتقدم لمرحلة دراسات امتصاص الخلايا بواسطة مقياس التدفق الخلوي والمجهر التلقائي؛ ودراسات السمية الخلوية بواسطة فحص MTT. **النتائج والمناقشة:** تم تحضير جسيمات TQ-PLGA النانوية المحسنة باستخدام w/v 1.02% شيتوسان، و w/v 1.14% مثبت، و 31% من قوة الصوتنة. تم تثبيت بقية المؤشرات كالتالي: 1:3 نسبة المرحلة الزيتية إلى المرحلة المائية، 1:5 نسبة المستحلب الأولي إلى وسط التشتت، 3% w/v تركيز PLGA، و 75:25 نسب المذيب النانوي لأسيتات إيثيل وثنائي كلورو الميثان. أظهرت جسيمات TQ-PLGA النانوية حجم 0.4 ± 147.2 نانومتر؛ ومؤشر تشتت متعدد 0.017 ± 0.142 ؛ وكمون زيتا 1.1 ± 22.1 ؛ وكفاءة كبسلة بنسبة $96.81 \pm 0.05\%$ ؛ وإطلاق ثنائي الطور $1.3 \pm 56.7\%$ خلال 24 ساعة و $1.3 \pm 69.7\%$ خلال أسبوع واحد. تم تجميع التركيبة المحسنة على شكل مسحوق ولكنها كانت مستقرة على شكل مستعلق لمدة 10 أيام. أظهرت الصيغة تحولاً زجاجياً منخفضاً لـ PLGA بدرجة حرارة أقل من 37 درجة مئوية مما يشير إلى التأثير التلديني لـ TQ والمكونات الأخرى مما ساهم في الإطلاق السريع بشكل عام. تم اختبار استقرار الـ TQ في الميثانول و جسيمات TQ-PLGA النانوية في وسائط استزرع كاملة، وأظهرت النتائج تدهور الـ TQ بنسبة 18% (في 24 ساعة) و بنسبة 77.0% (في 48 ساعة)، وظل حجم الجسيمات ثابتاً خلال 24 ساعة ولكن ظهرت تغيرات ملحوظة بعد 48 ساعة ($p < 0.05$)، وكانت تغيرات مؤشر التشتت المتعدد ملحوظة بعد 24 ساعة و 48 ساعة ($p < 0.05$)، ولوحظت تغيرات ملحوظة في كمون زيتا على التراكيز العالية لجسيمات TQ-PLGA النانوية ($p < 0.05$). كان أعلى امتصاص داخل الخلايا عند تركيز 1.0 مجم/مل من الجسيمات النانوية مع امتصاص خلوي معتمد على الوقت حتى 24 ساعة. بعد المعالجة لمدة 24 ساعة، تم حساب الـ IC₅₀ حيث بلغ 4.428 مجم/مل لجسيمات TQ-PLGA النانوية و 91.71 ميكروجرام/مل لـ TQ-مذيب. عند المعالجة لمدة 48 ساعة تم حساب IC₅₀ لجسيمات TQ-PLGA النانوية وبلغت 7.981 مجم/مل و 58.657 مجم/مل على التوالي. **الخلاصة:** تمت صياغة جسيمات TQ-PLGA النانوية المحسنة وأظهر سمية خلوية واعدة في خلايا A375. لدى TQ في صياغة الجسيمات النانوية استخدام واعد كمضاد للسرطان ويستحق دراسة إضافية في النماذج الحيوانية.

APPROVAL PAGE

I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Abd Almonem Doolaanea
Supervisor

.....
W isam Nabeel Ibrahim
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Juliana Md. JaffriInternal
Examiner

.....
Nurzalina Abdul Karim Khan
External Examiner

This thesis was submitted to the Department of Pharmaceutical Technology and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Muhammad Taher Bakhtiar
Head, Department of
Pharmaceutical Technology

This thesis was submitted to the Kulliyah of Pharmacy and is accepted as a fulfilment of the requirement for the degree of Master in Pharmaceutical Sciences (Pharmaceutical Technology).

.....
Che Suraya Bt. Hj. Mohd. Zin
Dean, Kulliyah of Pharmacy

DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Luqman Muizzuddin Bin Mohd Rosli

Signature

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF
FAIR USE OF UNPUBLISHED RESEARCH**

**FORMULATION OF THYMOQUINONE-LOADED PLGA
NANOPARTICLES AND CYTOTOXICITY IN MALIGNANT
MELANOMA A375 CELL LINE**

I declare that the copyright holders of this thesis are jointly owned by the student and IIUM.

Copyright © 2020 Luqman Muizzuddin Bin Mohd Rosli and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Luqman Muizzuddin Bin Mohd Rosli

.....
Signature

.....
Date

ACKNOWLEDGEMENT

Firstly, it is my utmost pleasure to dedicate this work to my dear parents and my family, who granted me the gift of their unwavering belief in my ability to accomplish this goal: thank you for your support and patience.

I wish to express my appreciation and thanks to those who provided their time, effort and support for this project. To the members of my thesis committee, thank you for sticking with me.

Finally, a special thanks to Dr. Abd. Almonem Doolaanea and Dr. Wisam Nabeel Ibrahim, for their continuous support, encouragement and leadership, and for that, I will be forever grateful. A special appreciation for all of science officer from Pharmaceutical Technology Department, Kuliyyah of Pharmacy, science officer from CREAM for their cooperation on providing me necessary tools and knowledge for me to finish the studies.

TABLE OF CONTENT

Abstract	ii
Approval Page.....	iii
Declaration	vi
Copyright	vii
Acknowledgement	viii
Table of Content	ix
List of Tables	xii
List of Figures	xiv
List of Abbreviations	xvii
CHAPTER ONE: INTRODUCTION.....	1
1.1 Background of the Study	1
1.2 Statement of the Problem.....	2
1.3 Research Objective	3
1.3.1 General Objective.....	3
1.3.2 Specific Objective	3
1.4 Research Questions.....	4
1.5 Flow of the Study	5
CHAPTER TWO: LITERATURE REVIEW	6
2.1 Malignant Melanoma Skin Cancer	6
2.1.1 Epidemiology	8
2.1.2 Treatment	8
2.2 Thymoquinone as Anticancer	12
2.3 Plga in Drug Delivery	14
2.4 Release Properties and Biodegradation of Plga.....	16
2.5 Common Excipients Used in Plga Nanoparticles Formulation	17
2.6 Fabrication of Nanoparticles.....	18
2.7 Nanoparticles in Cancer Treatment	19
2.8 Cell Uptake of Drug Carrier	20
CHAPTER THREE: VALIDATION OF ANALYTICAL PROCEDURE OF THYMOQUINONE LOADED NANOPARTICLES USING HPLC.....	22
3.1 Materials and Methods	23
3.1.1 Materials.....	23
3.1.2 Fabrication of Nanoparticles	23
3.1.3 Tq Analysis using Hplc.....	24
3.1.4 Analysis of Method Validation	25
3.1.5 Statistical Analysis	27
3.2 Results and Discussion	27
3.2.1 Specificity	27
3.2.2 Linearity and Range	36
3.2.3 Accuracy and Precision.....	37

3.3 Conclusion	38
CHAPTER FOUR: SCREENING OF FACTORS INFLUENCING TQ-PLGA NP FORMULATION USING FRACTIONAL FACTORIAL DESIGN	39
4.1 Materials & Method.....	41
4.1.1 Fabrication of Nanoparticles	42
4.1.2 Nanoparticles Characterisation	42
4.1.3 Design of Experiments	43
4.1.4 Statistical Analysis	44
4.2 Results	44
4.2.1 Screening Factors that Affect the Particle Size, Zeta Potential, and Encapsulation Efficiency	44
4.2.2 Statistical Evaluations on the Screening Factors Affecting Nanoparticles Formulations.....	46
4.3 Discussion.....	50
4.4 Conclusion	55
CHAPTER FIVE: OPTIMISATION OF THYMOQUINONE LOADED PLGA NANOPARTICLE FORMULATION USING FULL FACTORIAL DESIGN	56
5.1 Materials and Methods	57
5.1.1 Statistical Analysis	57
5.2 Fabrication of Nanoparticles.....	58
5.2.1 Characterization of Nanoparticles.....	58
5.3 Results and Discussion	60
5.3.1 Design of Experiment	60
5.3.2 Numerical Optimization of Nanoparticle.....	62
5.3.3 Characterization of Optimized Nanoparticles.....	64
5.4 Conclusion	73
CHAPTER SIX: CELL UPTAKE AND CYCOTOTOXICITY OF THYMOQUINONE LOADED PLGA NANOPARTICLES IN A375 CELLS	74
6.1 Materials and Methods	76
Reagents	76
6.2 Preparation and Characterisation of Nanoparticles	76
6.2.1 Stability of Tq-Plga Np And Tq in Cell Culture Media.....	77
6.3 Cell Culture and Cell Uptake Measurement.....	77
6.3.1 Cell Culture	77
6.3.2 Intracellular Uptake of Nanoparticles	78
6.4 Results and Discussion	81
6.4.1 Nanoparticle Characterization.....	81
6.4.2 Stability of Tq-Plga Np and Tq in Cell Culture Media.....	81
6.4.3 Intracellular Uptake of C6-Plga Np	86
6.4.4 In Vitro Anticancer Activity of Tq-Plga Nps.....	97
6.5 Conclusion	103
CHAPTER SEVEN: GENERAL DISCUSSION AND CONCLUSION	104

REFERENCES..... 108

LIST OF TABLES

Table 2.1	Show a number of medications that currently used to treat melanoma depending on the stage of the disease (“Melanoma : Treatment Options The cancer care team,” 2016).	10
Table 3.1	Retention time and peak area of TQ-PLGA NP and TQ Standard in 5 different stress conditions	28
Table 3.2	Accuracy, intraday, and interday precision of TQ analysis using HPLC	37
Table 4.1	Factors and levels applied in 2^{6-3} fractional factorial design.	43
Table 4.2	Design matrix of 2 fractional factorial designs and measured responses of particle size (Di50), zeta potential (mV), and encapsulation efficiency (%). These data responses were analyzed using Minitab software.	45
Table 4.3	ANOVA for particle size, zeta potential, and encapsulation efficiency and <i>p</i> -values (in bold) shows factors with significant impact on the factors studied.	46
Table 4.4	Regression model summary for each response.	47
Table 5.1	Representation of the factors with respective high and low levels which were randomised by Design Expert 7 software.	58
Table 5.2	Responses of particle size, PDI, and zeta potential for the optimization of formulation.	61
Table 5.3	The suggested formulation generated by software to acquire the target specifications.	62
Table 5.4	The range of acceptance in predicting responses. To acquire the required responses, it shall fall within the confidence interval and prediction interval as presented by design expert software.	63
Table 5.5	The stability of nanoparticle suspensions at four different storage condition post fabrication of nanoparticles	66
Table 6.1	The <i>t</i> -test of storage stability of TQ-PLGA NP for particle size, polydispersity index (PDI), and zeta potential in media incubated at 37 °C from 0 to 24 h and from 0 to 48 h.	83
Table 6.2	The degradation study on 100 µg/mL final concentration of TQ dissolved in methanol incubated in 2 mL of CGM at 37 °C for the period of 24 and 48 h.	84

Table 6.3	Cytotoxic effect of methanol towards A375 cells incubated at 37 °C for 24 h	97
Table 6.4	The <i>t</i> -test for comparison between cytotoxic effect of positive control (TQ-solution) at 24 h and 48 h. Symbol (*) represent significant difference between 24 and 48 h using t-test.	102
Table 6.6	The number of cells multiplied against the time.	103

LIST OF FIGURES

Figure 2.1	Normal anatomy of the skin	7
Figure 2.2	A, B, C, D, E shows representation of malignant melanoma of the skin. (Adapted from Gordon, 2013)	7
Figure 2.3	Structure of poly (lactic-co-glycolic acid). x= number of units of lactic acid; y= number of units of glycolic acid.	15
Figure 2.4	Solvent evaporation process for formulating PLGA nanoparticles	19
Figure 3.1	UV-Vis spectrum of TQ in methanol	28
Figure 3.2	Forced degradation studies by acid (HCl) (a) Blank nanoparticle (without TQ) (b) Sample nanoparticle (with TQ) (c) Standard (TQ)	30
Figure 3.3	Forced degradation studies by base (NaOH) (a) Blank nanoparticle (without TQ) (b) Sample nanoparticle (with TQ) (c) Standard (TQ)	31
Figure 3.4	Forced degradation studies by oxidation (1st hour) (a) Blank nanoparticle (without TQ) (b) Sample nanoparticle (with TQ) (c) Standard (TQ)	32
Figure 3.5	Forced degradation studies by temperature (50 °C) (a) Blank nanoparticle (without TQ) (b) Sample nanoparticle (with TQ) (c) Standard (TQ)	33
Figure 3.6	Forced degradation studies by UV (a) Blank nanoparticle (without TQ) (b) Sample nanoparticle (with TQ) (c) Standard (TQ)	34
Figure 3.7	Forced degradation studies by light (a) Blank nanoparticle (without TQ) (b) Sample nanoparticle (with TQ) (c) Standard (TQ)	35
Figure 3.8	Standard curve or linear regression of TQ using HPLC	36
Figure 4.1	Half normal plot of the standardized effects of (a) particle size, (b) zeta potential, and (c) encapsulation efficiency. The graph shows the magnitude of respective factors on the responses for nanoparticles formulation. Higher magnitude effect of the response was produced further to the right as compared to the left.	48

Figure 4.2	The effect of each factor (main effect) on the responses (a) particle size, (b) zeta potential, and (c) encapsulation efficiency. The idea of factor effect study can be observed in this figure relative to consequences of changing one level to another towards the responses.	49
Figure 5.1	Release profile of optimized TQ-PLGA NP formulation	64
Figure 5.2	SEM image of freeze-dried TQ-PLGA NP. Two points of each measurement (Pa1 – Pa R1 and Pa2 – Pa R2) were set to obtain the diameter of the nanoparticles.	68
Figure 5.3	FTIR spectra of PLGA NP, TQ-PLGA NP, and TQ	69
Figure 5.4	Thermogram of TQ and the PLGA.	71
Figure 5.5	Thermogram of TQ-PLGA NP.	72
Figure 6.1	Red circles indicate the changes indicated by TQ chromatogram. Sample was 100 µg/mL final concentration of TQ-solution dissolved in CGM in 24 and 48 h post incubation at 37 °C. This figure implies the extent of degradation of TQ in CGM if it were released from the nanoparticles outside the cell. Approximately, about 18.0 and 77.0 % degradation occurred in 24 and 48 h post incubation at 37 °C in CGM.	85
Figure 6.2	Flow cytometry analysis of the controls (a) free nanoparticles spiked in a media (positive control) and (b) untreated cells (negative control)	88
Figure 6.3	Flow cytometry analysis of A375 melanoma cells when incubated with coumarin-loaded nanoparticles in different concentration of nanoparticles suspension (a) 0.1 mg/mL, (b) 1.0 mg/mL, (c) 2.5 mg/mL, (d) 5.0 mg/mL, and (e) 10.0 mg/mL incubated for 24 h.	89
Figure 6.4	Flow cytometry analysis of A375 melanoma cells when incubated with coumarin-loaded nanoparticles treated with 1.0 mg/mL concentration of nanoparticles suspension at 3 different time points: (a) 2 h, (b) 6 h, and (c) 24 h.	90
Figure 6.5	Cellular uptake by mean fluorescence intensity (MFI) of C6-PLGA NP by A375 cell line at: (a) different concentration of nanoparticles and (b) by three different time of incubation.	91
Figure 6.6	Cellular uptake of C6-PLGA NP by A37 cell line visualized using fluorescence microscope at 40× and 100× magnifications. Green fluorescent detected were the C6-PLGA nanoparticles, while red fluorescent came from phalloidin dye and blue fluorescent on the nucleus was from DAPI.	96

Figure 6.7	A375 MTT assay for different concentrations of TQ-solution, mean \pm SD (n=3) for 24 and 48 h treatment period. Symbol (*) represent significant difference between 24 and 48 h using t-test.	99
Figure 6.8	A375 MTT assay for the treatment with blank and TQ-PLGA NP, mean \pm SD (n=3) for (a) 24 h and (b) 48 h.	101
Figure 6.9	The doubling time (min) of A375 cell lines against time (h), A375 cell growth were done in 6-well plate with starting cells concentration of 2.0×10^4	102

LIST OF ABBREVIATIONS

A375	Melanoma skin cancer cells
BRAF	BRAF is a human gene that encodes a protein called B-Raf
C6-PLGA NP	Coumarin-loaded Polylactic-Glycolic acid nanoparticles
CS	Chitosan
DAPI	4',6-diamidino-2-phenylindole (fluorescent stain)
D1	Day 1
D2	Day 2
DSC	differential scanning calorimetry
EE	encapsulation efficiency
EPR	enhanced permeability and retention
FTIR	Fourier – Transform Infrared Spectroscopy
HPLC	High Performance Liquid Chromatography
ICH guideline	International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline
ICH Q2	Validation of Analytical Procedures: Text and Methodology
LOD	Limit of detection
LOQ	Limit of quantification
MEK	Mitogen-activated protein kinase kinase enzymes MEK1 and/or MEK2
MSC	Melanoma skin cancer
NMSC	Non-melanoma skin cancer
PBS	phosphate buffer saline
PDI	Polydispersity index
PLGA	Poly(lactic-glycolic acid)
PS	Particle size
PVA	Polyvinyl alcohol
RSD	Relative standard deviation
SEM	Scanning Electron Microscopy
T80	Tween 80
TQ	Thymoquinone
TQ-PLGA NP	Thymoquinone-loaded Polylactic-Glycolic acid nanoparticles
TrypLE E	TrypLE express enzyme
UV	Ultraviolet
UV light	Ultraviolet light
ZP	zeta potential

CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND OF THE STUDY

Malignant melanoma of cell line A375 is a type of cancer develops from pigment containing cells called melanocytes and being featured as one of the top invasive of its kind, it has low prognostic value (Hofmann et. al, 2000). The metastatic type of its tumor development stage is among topmost aggressive and drug resistance. Patient's median survival time is about 5 – 6 years and has the survival rate less than 5% (Lens & Dawes, 2004).

Ahmad et. al, (2013) reported in his study the pharmacological properties of *Nigella Sativa* were attributes to quinine derivative called Thymoquinone (TQ) which present as most abundant active constituent (30% - 48%) in it as compared to other active compound like thymohydroquinone, dithymoquinone, p-cymene (7%-15%), carvacrol (6%-12%), 4-terpineol (2%-7%), t-anethol (1%-4%), sesquiterpene longifolene (1%-8%). TQ has been known to have therapeutic effect such as antimicrobial, antioxidants, hepatoprotective, anti-inflammatory and anticancer effects. It is believed that the mechanisms involved are inhibition of cell proliferation and eliciting apoptosis and necrosis mainly through interference of transcription factors, growth factors, inflammatory cytokines, protein kinases and other enzymes (Banerjee et. al, 2010). Nanotechnology in drug carrier system has skyrocketed in recent years which have led to more advanced treatment and ease diagnosis of many diseases including cancers.

Historically, the use of TQ came from revelation, the essence of Black cumin; the black seed oil (*Nigella Sativa*) has undergone tremendous studies for ages. The

black seed is one of the famous traditional medicines that were prescribed by prophet Muhammad (PBUHAHF) as narrated that the Prophet said: “this black seed is a healing for all diseases except Al-Sam.’ I said, ‘What is Al-Sam?’ He said: ‘Death’.” Narrated by Al-Bukhari (1976).

In couple of decades ago, PLGA has been of the most interesting polymer to be fabricated in application for drug delivery. PLGA is known for its biocompatibility and biodegradability and Food and Drug Administration (FDA) has approved its application for drug delivery and tissue engineering. This has resulted in extensive studies of PLGA development for controlled delivery of drugs, proteins and other macromolecules.

This study aims to develop a stable nanoparticle formulation for TQ and evaluate its cytotoxic effect in A375 cell line.

1.2 STATEMENT OF THE PROBLEM

Chemotherapeutic agents have many serious side effects such as risk of infections, risk of bleeding and prone to fatigue apart from other minor side effects (Gunjal et. Al., 2015). In the interest of these setbacks, TQ as natural product may offer as safer alternative to the chemotherapeutic drugs in treating melanoma skin cancer (Reddy, Odhav, & Bhoola, 2003). Yet an issue arises from the instability of TQ if administered alone as it degrades fast in aqueous environment (Salmani et. al, 2014). In case in parenteral route of administration, TQ may not reach insufficient concentration to the cancer site due to fast degradation and lack of targeting mechanism. Hence, the role of drug carrier is to encapsulate the TQ thus increase the stability in aqueous environment hence increasing therapeutic efficacy for treating melanoma. In addition,

it provides a tool for accumulating the drug in the cancer site due to the leaky nature of the cancer blood vessels.

Among other benefits of nano-drug delivery system besides provide stability in harsh environment are biodegradability, biocompatibility, high encapsulation characteristics, and probability of surface modification (Patravale, Dandekar, & Jain, 2012). The most important issue that lead to this study is TQ formulated in PLGA nanoparticles have yet to be studied in melanoma skin cancers and this study aim to test this dosage form in a stable formulation of TQ against the melanoma skin cancer cell lines.

1.3 RESEARCH OBJECTIVE

1.3.1 General Objective

To prepare and evaluate stable formulation of TQ-loaded PLGA nanoparticles (TQ_PLGA NP) through optimization of the formulation (particle size, zeta potential and efficiency) and the cell uptake and cytotoxicity.

1.3.2 Specific Objective

- 1) To validate an analytical method of quantifying TQ using HPLC.
- 2) To screen influencing factors affecting the formulation using fractional factorial design.
- 3) To formulate and optimize TQ-PLGA NP through full factorial design.
- 4) To evaluate the cell uptake of C6-PLGA NP and TQ-PLGA NP by A375 cell line
- 5) To study the cytotoxic effect of the optimized formulation on the cell line.

1.4 RESEARCH QUESTIONS

1. Can stable formulation of TQ-PLGA NP be formulated?
2. Will there be significant cell uptake of TQ-PLGA NP by malignant melanoma A375 cell line?
3. Will TQ-PLGA NP show cytotoxic effect on A375 cell line?

1.5 FLOW OF THE STUDY

Chapter 3: Analytical Method Validation of Thymoquinone Quantification using HPLC

- Specificity
- Linearity, LOD & LOQ
- Accuracy
- Precision

Chapter 4: Factor Screening by Fractional Factorial Design of experiments.

- Particle size, zeta potential and encapsulation efficiency analysis
- Determination on most influential factors

Chapter 5: Fabrication And Optimisation of Nanoparticles

1. Full factorial studies, Optimisation
2. Characterisation
 - a. Surface morphology
 - b. DSC and FTIR
 - c. Particle size, PDI and zeta potential analysis
 - d. Encapsulation efficiency
 - e. In-vitro release studies (1 week)
 - f. Stability studies (10 Days)

Chapter 6: Cell Uptake study by A375 Cell Line

1. A375 Cell culture preparation
2. Cell uptake analysis through Flow Cytometry

Chapter 6: Study the cytotoxic effect of optimised formulation on A375 cell line.

1. A375 Cell culture preparation
2. Cell viability and cell cytotoxicity studies determined by MTT Assay

CHAPTER TWO

LITERATURE REVIEW

2.1 MALIGNANT MELANOMA SKIN CANCER

Malignant melanoma is a cancerous skin disease of melanocytes; cells located on the lower part of epidermis and responsible for melanin secretion, the pigment of skin. Figure 2.1 shows the anatomy of human skin. In normal physiologic condition, melanocytes create melanin and cause darker skin under ultraviolet (UV) exposure. Melanoma can be initiated anywhere on the skin surface and even though melanoma cases are uncommon, melanoma tends to initiate tissue invasion and spread to other body parts when it becomes cancerous. Solar UV radiation exposure, age, fair complexion, history of skin cancer, genetic factors or family history of melanoma malignancies, infection with human papilloma virus, weak immune system, organ transplantation and use of tanning beds are some risk factors that have been linked to melanoma (America Cancer Society, 2013; Gordon, 2013). The visual presentation of malignant melanoma is shown in Figure 2.2.




Figure 2.1 Normal anatomy of the skin
 Source: The National Cancer Institute, available at
<https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq>




Figure 2.2 A, B, C, D, E shows representation of malignant melanoma of the skin.
 (Adapted from Gordon, 2013)